Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus

Core Points - Lipella Pharmaceuticals Inc. announced that CEO Jonathan Kaufman will present a corporate overview and final results from the Phase 2a trial of LP-10 in oral lichen planus at the Zacks SCR Life Sciences Virtual Investor Forum on September 18, 2025 [1] - The event will be a live, interactive online forum allowing investors to ask questions in real-time, with an archived webcast available for those unable to attend live [2][3] Company Overview - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs, targeting diseases with significant unmet needs [4] - The company completed its initial public offering in 2022 and aims to optimize reformulations for new applications [4]